Lipofundin Mct (Soya-Bean Oil Refined, Triglycerides, Medium Chain)

Lipofundin Mct is a parenteral nutrition lipid emulsion used to support caloric and essential fatty‑acid needs in patients unable to receive enteral feeding.

• Parenteral nutrition in patients who cannot receive enteral feeding: supplies calories and essential fatty acids when oral or tube feeding is not possible.
• Supplementation of essential fatty acids in critically ill patients: helps maintain membrane integrity and modulate inflammation.
• Postoperative nutritional support: provides energy and fatty acids during recovery after major surgery.

• The emulsion delivers medium‑chain triglycerides and soy‑derived long‑chain fatty acids that are rapidly hydrolysed to free fatty acids, providing an immediate energy source. Essential fatty acids are incorporated into cell membranes, while phospholipids support lipoprotein synthesis and immune function, collectively sustaining metabolic needs during parenteral nutrition.

Adverse reactions may occur during or after infusion.

Common Side Effects

• Hypertriglyceridemia: elevated blood triglyceride levels.
• Fever: mild temperature rise during infusion.
• Phlebitis: inflammation at the infusion site.
• Nausea: feeling of sickness.
• Hypersensitivity rash: skin reaction.

Serious or Rare Side Effects

• Fat overload syndrome: severe metabolic disturbance.
• Acute respiratory distress: breathing difficulty.
• Anaphylaxis: severe allergic reaction.
• Hepatic dysfunction: liver enzyme elevation.

When using Lipofundin Mct, consider the following safety measures.

• Patient assessment: evaluate baseline triglyceride levels before initiating therapy.
• Monitoring: check serum lipids and liver function regularly during treatment.
• Infusion rate: administer at the recommended rate to reduce risk of fat overload.
• Compatibility: verify compatibility with other IV solutions before mixing.
• Special populations: use caution in patients with pancreatitis or severe liver disease.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed before initiating therapy.

Major Interactions (Avoid)

• Propofol: concurrent use may increase triglyceride levels and risk of fat overload.
• Lipid‑soluble drugs (e.g., certain antibiotics): may alter drug distribution and efficacy.

Moderate Interactions (Monitor Closely)

• Heparin: may potentiate triglyceride reduction, monitor lipid profile.
• Warfarin: lipid emulsion may affect INR, monitor coagulation.
• Steroids: may increase serum lipids, observe levels.